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Background: Resource constraints in low and middle-income countries(LMICs) 
necessitate practical approaches to optimizing antiretroviral therapy outcomes. We 
hypothesised that an untimed plasma lopinavir concentration(UPLC) at week 12 
would predict loss of virological response in those taking lopinavir as part of a 
second-line antiretroviral regimen.  
 
 
Methods: We measured plasma lopinavir concentration at week 12 on stored samples 
from the SECOND-LINE study. We characterised UPLC as: (a) detectable and 
optimal (≥1000 µg/L); (b) detectable but sub-optimal (≥25 to < 1000 µg/L); (c) 
undetectable (< 25 µg/L). We used Cox regression to explore relationship between 
UPLC and loss of virological response over 48 weeks and backwards stepwise logistic 
regression to explore the relationship between UPLC and other predictors of 
virological failure(VF) at week 48.  
 
 
Results: At week 48 we observed VF in 15/32 (47%) and 53/485 (11%) of patients 
with undetectable and detectable UPLC, respectively, p<0.001. Both suboptimal 
(adjusted HR 2.94, 95% CI 1.54 - 5.62, p=0.001), and undetectable (adjusted HR 
3.55, 95% CI 1.89 - 6.64, p<0.001) UPLC were associated with higher rates of loss of 
virological response over 48 weeks. In multivariate analysis, an independent 
association with VF at week 48 and undetectable UPLC was observed after 






Conclusions:  In LMICs implementing a public health approach to ART treatment, 
untimed plasma drug concentration may provide a practical method for early 
identification of patients with inadequate medication adherence and facilitate timely 
corrective interventions to prevent virological failure. 
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Optimising second-line antiretroviral therapy(ART) outcome is critical to achieving 
the global UNAIDS “90–90–90” targets. Worrying trends of increasing second-line 
regimen failure in low and middle-income countries (LMICs) pose significant 
challenges to global efforts to achieving these targets [1]. 
 
 
Boosted protease inhibitors (PIs) are the World Health Organisation(WHO) - 
recommended and preferred anchor drugs for second-line ART regimens [2].  PI-
based regimens have demonstrated a characteristic adherence-response relationship 
[3,4]. While regimen potency is key for virological suppression, and near complete 
(95%) adherence is critical to assure full and sustained virological suppression, the 
levels of adherence required for the selection of boosted PI resistance is unknown 
[5,6].  While high adherence level of 95% has been associated with optimal viral 
suppression [7], high rates of viral suppression have also been documented among 
patients with moderate levels of adherence [8,9]. 
 
 
We have previously demonstrated that higher baseline HIV RNA viral load (VL), 
poor adherence (<100%), greater degrees of study baseline N(t)RTI resistance and 
ethnicity independently predicted virological failure at week 96 [10]. 
 
 
We decided to extend these observations by assessing whether an early untimed 




virological suppression, defined as VL< 200 copies/mL and virological failure, 
defined as VL ≥200 copies/mL at week 48. We were also interested in determining if 
the independent association between virological failure and ‘ethnicity’ would remain 
if we controlled for plasma ART concentration.  
We hypothesised that an untimed plasma lopinavir concentration (UPLC) measured at 




Participants and trial design 
SECOND-LINE was an international, multicentre, open-label, randomised controlled 
trial comparing ritonavir-boosted lopinavir given with either two or three N(t)RTIs 
(N(t)RTI group) or with raltegravir (RAL group) as second-line therapy. [11] Of 558 
participants, 41 were excluded for either switching off ritonavir-boosted lopinavir 
prior to week 12 or having an inadequate stored plasma samples at week 12. 
 
 
Materials and Methods 
We retrospectively analysed week 12 plasma lopinavir concentration using stored 
patient samples obtained from the SECOND-LINE study repository in Sydney, 
Australia.  We measured lopinavir concentration using High-Performance Liquid 
Chromatography. The method allows for accurate and precise quantitation of samples 
from 100 µg/L - 15,000 µg/L with the lower limit of detection (LLD) of 25 µg/L. All 










The primary objective of this study was to investigate the association between 
untimed detectable (LPV≥25 µg/L) or undetectable (LPV<25 µg/L) plasma LPV at 
week 12 and virological failure at week 48 (HIV viral load in plasma≥200 
copies/mL). Secondary objectives included the association between untimed plasma 
lopinavir concentration (UPLC) as (a) detectable and optimal (o-UPLC) (≥1000 
µg/L); (b) detectable but sub-optimal (s-UPLC) (≥25 to <1000 µg/L); (c) undetectable 




 A chi-square test was used to examine the association between UPLC and virological 
failure at week 48.Univariate logistic regression was used to assess the association 
between virologic failure at week 48 and UPLC as well as other correlates of 
virologic outcome (age, BMI, sex, ethnicity, duration of HIV infection, HIV stage, 
duration of ART, randomized arm, baseline VL, nadir CD4, baseline CD4, baseline 
CD8, baseline CD4/CD8 ratio, adherence at week 4, adherence at week 48, baseline 
resistance (genotypic sensitivity score [GSS]) and HIV subtype). Kaplan-Meier 
methods and Cox regression models were used to investigate the relationship between 
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Our analysis included 517 of 558 participants enrolled into the SECOND-LINE trial 
who were receiving lopinavir at week 12 and had an adequate stored sample available. 
At week 48 we observed virological failure in 15/32 (47%) and 53/485 (11%) of 
patients with undetectable and detectable plasma lopinavir concentrations, 
respectively, p<0.001. At week 12, 32/517 (6%) had undetectable UPLC, and 485/517 
(94%) had detectable UPLC.  
 
 
Both suboptimal UPLC (adjusted HR 2.94, 95% CI 1.54 - 5.62, p=0.001), and 
undetectable UPLC (adjusted HR 3.55, 95% CI 1.89 - 6.64, p<0.001) were 
significantly associated with higher rates of loss of virological response over 48 
weeks after adjusting for baseline viral load and randomized arm, Fig.1.  
In multivariate analysis, an independent association with time to loss of virological 
response over 48 weeks and undetectable UPLC was observed after adjustment for 
baseline GSS, baseline VL, baseline BMI, adherence at week 4 and week 48 and 
ethnicity (OR 5.48, 95% CI 2.23 - 13.42, p< 0.001), (Table1).  
 
 
The association between VF at week 96 and ethnicity observed in our previous 




p=0.196, Hispanics; OR 3.13; 95%CI 1.21 – 8.13; p = 0.019 and Africans; OR 2.09; 
CI 0.7 – 6.25; p= 0.185) [10] lost significance with the inclusion of the week 12 
UPLC data in the current analysis (Whites as a comparator group: Asians; OR 0.43; 




We observed a significant association between single undetectable UPLC and 
virological failure among an ethnically diverse cohort of HIV patients randomised to 
LPV/r as part of a second-line therapy.  
 
 
Early and objective identification of poor adherence is critical to achieving and 
sustaining viral suppression. Self-reported adherence for example, while it is cheap 
and easy to administer, is prone to recall bias and overestimation [12,13]. 
Underestimation of true adherence and patients’ acceptability of medication event 
monitoring systems(MEMS) has been previously reported [14]. 
 
 
Several studies have demonstrated the relationship between untimed plasma or hair PI 
concentrations and virological outcome [12–23]. A significant association between a 
single, low, plasma drug level soon after starting unboosted PI therapy and poor 
virological outcome[adjusted OR,2.7; CI, 0.10 – 0.72; p<0.001] during the first year 
of therapy was reported by Alexander et al. [13]. In a retrospective analysis of plasma 




virological suppression  at 3 months among those patients with subtherapeutic (LPV< 
3 mg/L), therapeutic concentration (LPV= 3mg/L - 8 mg/L) and toxic concentration 
(LPV> 8 mg/L), p< 0.05 ten days after commencing LPV/r containing regimen [24]. 
In a cross-sectional analysis of 93 patients treated with LPV/r regimens, low plasma 
LPV (< 1 μg/ml) had negative predictive value for virologic 
failure(VL>1000copies/ml) of 92% [17]. 
 
 
In contrast to the above studies, we used untimed plasma LPV at week 12 in  a 
contemporary cohort of 517 patients, in a randomized trial setting, who were 
receiving LPV/r based, WHO recommended second-line regimens, to predict 




Our findings have important clinical implications. Firstly, the measurement of 
untimed plasma drug concentration may provide a simple and practical method for the 
identification of patients with inadequate adherence and impending virological failure. 
This approach might allow early tailored adherence interventions before virologic 
failure and selection of resistance mutations to facilitate viral re-suppression and 
optimise treatment outcome [25]. At less than US$50 per sample, one could imagine 
for instance the development and use of a simple point of care test that reported 





Secondly, even with an ethnically diverse population, ethnicity or racial categories are 
weak proxies for interrogating differential virologic outcomes with contemporary, 
potent, highly forgiving ART regimens. While it may be tempting to explain higher 
rates of virological failure by ethnically-determined drug distribution and metabolism, 
we have demonstrated that virological failure in the SECOND-LINE study was more 
likely simply a marker of poor adherence.  
 
 
Strategies to optimise adherence will be critical to the long-term success of ART 
programs worldwide. While third-line ART is mentioned in WHO guidelines, it is 




The study has some weaknesses. Plasma ART  concentration can be  influenced by 
sex, age, BMI, drug-drug interactions, drug-food interaction, disease state, drug 
transporters and genetic polymorphism [26–28] . 
We measured LPV/r at a single time point thus limiting our ability to interrogate inter-
personal and intra-personal variability [29] of the plasma LPV concentrations. In 
some individual cases, we were unable to analyse the relationship between plasma 
lopinavir concentration and virological outcome due to missing or inadequate plasma 
samples. These phenomena partly explain the imperfect association between UPLC 







In LMICs, where a public health approach to the provision of HIV treatment is widely 
implemented, single untimed LPV concentration offers a practical method for 
adherence stewardship, optimising treatment outcome to boosted PI-based therapy 
and ensuring sustainability of ART treatment programs. This may be even more 
attractive if a simple point-of-care technology could determine the absence or 
presence of LPV were available. Further study using untimed LPV or other PI plasma 
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